Intrapleural extravasation of epirubicin, 5-fluouracil, and cyclophosphamide, treated with dexrazoxane

Author： Uges Joris W.F.   Vollaard Albert M.   Wilms Erik B.   Brouwer Rolf E.  

Publisher： Springer Publishing Company

ISSN： 1341-9625

Source： International Journal of Clinical Oncology, Vol.11, Iss.6, 2006-12, pp. : 467-470

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Dexrazoxane use in the prevention of anthracycline extravasation injury

By Hasinoff Brian B  

Future Oncology, Vol. 2, Iss. 1, 2006-02 ,pp. : 15-20

Future Medicine

Access to resources Recommend Favorite

A New Conservative Approach to Extravasation of Anthracyclines with Dimethylsulfoxide and Dexrazoxane

By Bos Annelies M. E.   van der Graaf Winette T. A.   Willemse Pax H. B.  

Acta Oncologica, Vol. 40, Iss. 4, 2001-06 ,pp. : 541-542

Informa Healthcare

Access to resources Recommend Favorite

Individually tailored toxicity-based 5-fluorouracil, epirubicin and cyclophosphamide (FEC) therapy of metastatic breast cancer

By Lindman Henrik   Åström Gunnar   Ahlgren Johan   Villman Kenneth   Blomqvist Carl   Nygren Peter   Bergh Jonas  

Acta Oncologica, Vol. 46, Iss. 2, 2007-01 ,pp. : 165-171

Informa Healthcare

Access to resources Recommend Favorite

Randomized phase III trial of adjuvant epirubicin followed by cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) versus CMF followed by epirubicin in patients with node-negative or 1–3 node-positive rapidly proliferating breast cancer

By Amadori Dino   Silvestrini Rosella   Lena Mario   Boccardo Francesco   Rocca Andrea   Scarpi Emanuela   Schittulli Francesco   Brandi Mario   Maltoni Roberta   Serra Patrizia   Ponzone Riccardo   Biglia Nicoletta   Gianni Lorenzo   Tienghi Amelia   Valerio Maria   Bonginelli Paola   Amaducci Laura   Faedi Marina   Baldini Editta   Paradiso Angelo  

Breast Cancer Research and Treatment, Vol. 125, Iss. 3, 2011-02 ,pp. : 775-784

Springer Publishing Company

Access to resources Recommend Favorite

Randomized trial of preoperative docetaxel with or without capecitabine after 4 cycles of 5-fluorouracil–epirubicin–cyclophosphamide (FEC) in early-stage breast cancer: exploratory analyses identify Ki67 as a predictive biomarker for response to neoadjuvant chemotherapy

By Ohno S.   Chow L.   Sato N.   Masuda N.   Sasano H.   Takahashi F.   Bando H.   Iwata H.   Morimoto T.   Kamigaki S.   Nakayama T.   Nakamura S.   Kuroi K.   Aogi K.   Kashiwaba M.   Yamashita H.   Hisamatsu K.   Ito Y.   Yamamoto Y.   Ueno T.   Fakhrejahani E.   Yoshida N.   Toi M.  

Breast Cancer Research and Treatment, Vol. 142, Iss. 1, 2013-11 ,pp. : 69-80

Springer Publishing Company

Access to resources Recommend Favorite